Almirall, Novo Nordisk Reach Licensing Agreement Surrounding IL-21 Blocking Monoclonal Antibodies
As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.
FDA Accepts Biologics License Application for Datopotamab Deruxtecan
The agency will make its final decision surrounding the locally advanced or metastatic nonsquamous NSCLC drug —based on results from the TROPION-Lung01 Phase III trial—by Q4 2024.
ValGenesis, RxCloud Collaborate on Tackling Compliance and Quality Assurance Challenges
The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.
Schreiner MediPharm Unveils New Closure Seals for Pharma Packaging
The new seals include sustainable film material containing recyclate content of up to 90%.
DHL Supply Chain Invests $200M Toward Expanding Its Life Sciences and Healthcare Services
The financial commitment features construction of new warehouses in Pennsylvania and North Carolina.
Using Machine Learning to Predict Cancer Treatment Effectiveness
Scientists develop algorithms that can not only identify tumors that will respond well to chemotherapy, but which are also likely to resist treatment.
How Are High Drug Prices Justified?
Analysis explores where drug prices are derived from, and whether a holistic societal approach can help determine these products’ true value.
Analyzing State-Based Legislation Surrounding Medical Freedom, Stem Cell Procedures
Examination evaluates investigational stem cell interventions, including how the states have implemented their own policies when it comes to their uses.
Can Lower Out-of-Pocket Costs Help Improve Diabetes Patients’ Short-Term Health?
Cohort study explores value-based insurance designs, while also determining how one’s place of residency can potentially play a role.
Study Highlights the Value of Patient Support Programs
Researchers explore the proportion of approved drugs in the Canadian marketplace that utilize manufacturer-sponsored patient support programs, along with the types of medications that are more likely to do so.
Erectile Dysfunction Meds Could Be Associated With Lowering Alzheimer's Disease Risk
Investigators examine the validity of phosphodiesterase type 5 inhibitors for erectile dysfunction, such as Viagra, being repurposed for the treatment of Alzheimer's disease.
Determining the Efficacy of Bivalent COVID-19 Vaccines in Children and Adolescents
A study investigates the effectiveness of bivalent mRNA COVID-19 vaccines against the Omicron variant among participants 5-17 years of age.
BridgeBio Pharma Receives FDA Acceptance of New Drug Application Filing for Acoramidis
Trial for the treatment of ATTR-CM demonstrated an 81% absolute survival rate, along with an observed mean annual CVH frequency of 0.29.
Exploring the Frequency That Beneficiaries Encounter Subsidy Losses Attributed to Medicare Part D’s Low-Income Subsidy Program
Cohort study dives into whether low income subsidy losses are associated with disability status, age, and race and ethnicity.
The Correlation Between a New York State Law Repeal and Vaccine Coverage in Schools
A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?
New Year, New Aspirations
Pharma Commerce's new style is built off of the back of our new and improved editorial calendar.
Access Insights and Information Abound
Pharma Commerce travels to Orlando for a pulse-check on this fast-evolving landscape in patient care.
A Comparison of Prescription Drug Availability
An analysis conducted by RAND Corporation determines that majority of new Rx medications are first sold in the United States before making their debut in other countries.
The Path for Prescription Drug Sales
A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.
Peeking Behind the Curtain: The Current State of Pharma 3PLs and Future Outlook
Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.
Forecasting the Effect of Out-of-Pocket Cost Changes for HIV Medication
Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.
A Behind-the-Scenes Look at Drug Price Markups
New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures.
The Association Between Cannabis Legalization and Opioid Overdoses
Cohort study aims to determine whether or not these regulatory changes in state government have helped reverse opioid mortality rates.
Does Patient Priorities Care Result in Better Outcomes for Patients?
A non-randomized control trial investigates whether older adults with multiple chronic conditions can benefit by receiving more specialized services.
Examining the Liability Risk Surrounding Artificial Intelligence Tools in the Healthcare Environment
As technology continues to advance, investigators explore the legal protocol for how to handle AI-responsible injuries.
Complying With the DSCSA
Dave DeJean provides his expert insight on lessons he’s learned from his plethora of time in the industry, along with an outlook on where the pharma supply chain stands in adhering to the Drug Supply Chain Security Act (DSCSA).
Using Blockchain to Minimize Consumers’ Risk Aversion Toward Generic Drugs
Study describes how a game theoretic model can successfully analyze how adoption of blockchain technology can reveal quality information.
How Financialization Has Impacted the US Healthcare System
Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.
The Evolving Role of PBMs: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group
In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.
The Impact of Eli Lilly's New DTC Platform on Rx Drug Sales and Patient Access: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group
In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.